1. Home
  2. GNL vs COAG Comparison

GNL vs COAG Comparison

Compare GNL & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Net Lease Inc.

GNL

Global Net Lease Inc.

HOLD

Current Price

$8.67

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$36.73

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNL
COAG
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2011
2026

Fundamental Metrics

Financial Performance
Metric
GNL
COAG
Price
$8.67
$36.73
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$9.67
N/A
AVG Volume (30 Days)
1.7M
377.8K
Earning Date
05-05-2026
N/A
Dividend Yield
7.98%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$495,286,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.48
$27.47
52 Week High
$10.04
$55.42

Technical Indicators

Market Signals
Indicator
GNL
COAG
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GNL
COAG

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operation, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution, Retail, and Office. The company derives maximum revenue from the Industrial and Distribution segment. The company geographically operates in the United States, the United Kingdom, Canada, and Europe.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: